Probiotics and methotrexate for early psoriasis
Treatments studied
Part of Skin clinical trials.
This pilot study tests whether adding probiotics to standard methotrexate treatment improves symptoms in people newly diagnosed with chronic plaque psoriasis. It aims to see how the gut microbiome affects treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with chronic plaque psoriasis (red, scaly patches on the skin).
- You have not used psoriasis medications that affect the whole body (like biologics or oral treatments) in the last 3 months, except for acitretin, which cannot have been used in the last 3 years.
- You do not have other skin diseases or autoimmune conditions (such as lupus, lichen planus, dermatomyositis, or vitiligo).
- You are not pregnant or breastfeeding.
- You have no conditions that make methotrexate unsafe (your doctor will check this).
- You are willing to take probiotics daily and report your progress over 16 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding an antidepressant (escitalopram) to standard methotrexate treatment works better than methotrexate alone for people who have both psoriasis and depression or anxiety. If you have moderate to severe psoriasis and also struggle with depression or anxiety, this study might offer a way to treat both conditions together.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
This study tests whether combining narrowband UVB light therapy with methotrexate helps treat moderate to severe plaque psoriasis. It looks at a blood marker called gelsolin to see if treatment reduces inflammation.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study compares two systemic medications—methotrexate (a traditional immunosuppressant) and tofacitinib (a newer targeted therapy)—to see which works better for moderate-to-severe plaque psoriasis that hasn't responded well to creams or ointments.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.